The induction chemotherapy regimen used in this study was a lower intensity version of conventional hyper-CVAD (hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with methotrexate and high-dose cytarabine) and referred to as mini-hyper-CVD, which reduces cyclophosphamide and …Web
قرأ أكثر
Both 30 s and 30 min of low-intensity ultrasound was used to stimulate brain tissue at the induction window . The 2-dimensional distribution of the ultrasound field measured by a calibrated needle-type hydrophone (HNR500, Onda) is plotted in Fig. 3B. As the ultrasound transducer and the coupling cone are placed obliquely, the cross section …Web
قرأ أكثر
Ph+ ALL is defined by the presence of a translocation between chromosomes 9 and 22, with t (9;22) (q34;q11) being the most common chromosomal abnormality. 1, 2 …Web
قرأ أكثر
The paradigm of the low-intensity approach, low-dose cytarabine, has been used for decades in patients deemed unsuitable for intensive induction. In a large …Web
قرأ أكثر
Patients receiving low intensity induction continued a low intensity approach until transplant unless additional "salvage" therapy was required for management of refractory disease prior to entering CR1. These patients remained in the low intensity cohort for analysis. All patients received central nervous system (CNS) prophylaxis with ...Web
قرأ أكثر
Background and Objectives: This study aimed to evaluate whether the addition of hypomethylating agents (HMA) to low-intensity chemotherapy can enhance the clinical efficacy of induction treatment for elderly acute myeloid leukemia (AML) patients who are unsuitable for standard induction therapy.Materials and Methods: This study …Web
قرأ أكثر
Recently, with effective non-intensive options, such as venetoclax (Ven) combinations, or IDH inhibitors, we offered low intensity re-induction to select pts with persistent disease after initial intensive therapy as a potential means of reducing morbidity, and potentially improving chance for response. This study describes the characteristics ...Web
قرأ أكثر
Background and Objectives: This study aimed to evaluate whether the addition of hypomethylating agents (HMA) to low-intensity chemotherapy can enhance the clinical efficacy of induction treatment for elderly acute myeloid leukemia (AML) patients who are unsuitable for standard induction therapy. Materials and Methods: This study …Web
قرأ أكثر
The therapeutic effects of low intensity pulsed ultrasound (LIPUS) on renal ischemia/reperfusion injury (IRI) with acute kidney injury (AKI) are still unclear. A renal tubule cell model under H2O2 ...Web
قرأ أكثر
Low-intensity regimens for AML. Standard low-intensity regimens utilize LDAC or HMAs. LDAC corresponds to various dose schedules with doses inferior to 50 mg/day given as subcutaneous injections. No standard schedule has yet been …Web
قرأ أكثر
The use of lower intensity therapies in this population has become routine. The inclusion of venetoclax to intensify a hypomethylating agent backbone has efficacy …Web
قرأ أكثر
Patients with newly diagnosed, relapsed, or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS) are often treated with intensive induction chemotherapy with the goal of achieving complete remission. 1,2 This treatment routinely causes pancytopenia, rendering patients susceptible to life …Web
قرأ أكثر
The prognosis of elderly patients with acute myeloid leukemia (AML) is poor, and the recommendation of standard-dose or low-intensity induction regimen for these patients remains controversial. We retrospectively analyzed treatment outcome and prognostic factors of elderly AML patients who had received either standard-dose or low-intensity ...Web
قرأ أكثر
The more important comparison which is not reported here is the difference between high-intensity (e.g., 7+3) and low-intensity (e.g., azacitidine + venetoclax) therapy. In most institutions, 4 all patients receiving intensive induction chemotherapy are admitted to the hospital for approximately 4 weeks. This is followed by three cycles of ...Web
قرأ أكثر
Low intensity pulsed ultrasound (LIPUS) has been demonstrated to possess therapeutic effects on neuronal diseases and stroke via brain-derived neurotrophic factor (BDNF) induction. In this study, we hypothesized that LIPUS treatment possessed therapeutic benefits for the improvement of stroke recurrence.Web
قرأ أكثر
Introduction. Acute myeloid leukemia (AML) is the second most common leukemia in adults. In 2019, an estimated 21,450 new cases and 10,920 deaths were reported in the United States. 1 Older adults account for most cases, with a median age of 68 years at diagnosis. Incidence rates of AML increase with age from 1.3 per 100,000 in …Web
قرأ أكثر
The initial data for the most widely utilized intensive induction chemotherapy regimen for acute myeloid leukemia (AML), a combination of cytarabine and an anthracycline ("7+3"), were published in 1973. 1 In the subsequent four decades the question of increasing or decreasing the intensity of induction had been asked multiple times.Web
قرأ أكثر
In this study, we (1) report the outcomes of children with AML who received low-intensity induction chemotherapy, and (2) evaluate the quality of remission by using next-generation sequencing. From July 2012 to May 2016, 90 Chinese children with AML who had white blood cell counts less than 50.0×10 9 /L were treated at a single center. …Web
قرأ أكثر
When evaluating low-intensity therapies for acute myeloid leukemia (AML), emphasis is usually placed on inpatient versus outpatient management of patients. In …Web
قرأ أكثر
Patients selected based on a combination of presenting features and a minimal residual disease (MRD) level <0.01% on day 19 of induction therapy had excellent outcomes with low-intensity treatment. We investigated the impact of MRD levels between 0.001% and <0.01% early in remission induction on the outcome of VLR ALL treated …Web
قرأ أكثر
Effect of induction intensity and ASCT in CR1 on patients stratified by karyotypic complexity. In those patients with a CK, treatment with an intensive cytarabine containing induction regimen vs low-intensity regimen had no statistically significant effect on median OS (4.5 vs 3.8 years, p=0.77) nor median PFS (2.3 vs 1.5 years, p=0.45).Web
قرأ أكثر
There are two key laws that describe electromagnetic induction: Faraday's law, due to 19ᵗʰ century physicist Michael Faraday. This relates the rate of change of magnetic flux through a loop to the magnitude of the electro-motive force E. . …Web
قرأ أكثر
Low-intensity ultrasound (LIUS) is a promising therapy for various inflammatory diseases, but its molecular mechanisms are not fully understood. This article reviews the current evidence on how LIUS modulates inflammation and tissue repair, focusing on the roles of microRNAs, immunosuppressive cells, and exosomes.Web
قرأ أكثر
Low Intensity Alternative Induction Therapy for Acute Myeloid Leukemia (AML). Real World Experience from Tawam Hospital, United Arab Emirates ... intermediate risk n= 9 poor risk n=3, metaphase failure n=4. Alternative induction reasons included age (n=9), co-morbidities (n=10) (Obesity, respiratory failure, cardiomyopathy, pul- monary …Web
قرأ أكثر
In this study, we (1) report the outcomes of children with AML who received low-intensity induction chemotherapy, and (2) evaluate the quality of remission by using next-generation sequencing. From July 2012 to May 2016, 90 Chinese children with AML who had white blood cell counts less than 50.0×10 9 /L were treated at a single center.Web
قرأ أكثر
There was no difference between the low and high induction intensity cohorts in the proportion of patients requiring a salvage regimen to achieve CR1 (14% vs. 16%, p=0.77). Following induction, molecular MRDneg status was similar in the low and high intensity cohorts (54% and 52% respectively, p=0.99).Web
قرأ أكثر
In conclusion, dasatinib combined with low-intensity chemotherapy was well-tolerated and gave long-term survival in 36% of elderly patients with Ph(+) ALL. Monitoring of BCR-ABL1(T315I) from diagnosis identified patients with at high risk of early relapse and may help to personalize therapy.Web
قرأ أكثر
Low-intensity HMA therapy with decitabine and azacitidine-based regimens is now the most common form of treatment among older ... Induction mortality from DIC is low (about 5%). Resistant disease is extremely rare, except in molecular variant-APL (translocations between chromosome 11 and 17 ...Web
قرأ أكثر